Karim S. Fizazi

Q: What Schools Are Affiliated With Karim S. Fizazi

Karim S. Fizazi is affiliated with the following schools: University of Liverpool, Université de Montréal, Tampere University, Paris-Saclay University, University of British Columbia, Cardiff University, Sapienza University of Rome, Massachusetts General Hospital

Karim S. Fizazi's AcademicInfluence.com Rankings

Karim S. Fizazi

Medical

#1384

World Rank

#1717

Historical Rank

Oncology

#59

World Rank

#63

Historical Rank

medical Degrees

Karim S. Fizazi

Philosophy

#4429

World Rank

#6937

Historical Rank

Logic

#1880

World Rank

#2742

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Karim S. Fizazi's Degrees

Doctorate Medicine Université Paris Cité
PhD Cancer Biology Université Paris Cité

Why Is Karim S. Fizazi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Karim S. Fizazi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Abiraterone and increased survival in metastatic prostate cancer. (2011) (3933)
Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012) (3907)
Abiraterone in metastatic prostate cancer without previous chemotherapy. (2013) (2446)
Enzalutamide in metastatic prostate cancer before chemotherapy. (2014) (2357)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (2011) (1785)
Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer (2017) (1387)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. (2014) (1201)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. (2012) (1189)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) (1059)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2020) (878)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial (2012) (728)
Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer (2018) (682)
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. (2008) (556)
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. (2013) (541)
Guidelines on Testicular Cancer: 2015 Update. (2015) (525)
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. (2009) (514)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (2012) (498)
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. (2012) (491)
Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer (2019) (481)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) (478)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017) (477)
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). (2004) (476)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. (2014) (391)
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas (2011) (368)
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. (2019) (364)
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data (2016) (360)
EAU guidelines on testicular cancer: 2011 update. (2011) (344)
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. (2016) (338)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (2019) (323)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. (2019) (306)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration (2020) (298)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). (2013) (293)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (2020) (283)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. (2012) (272)
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer (2012) (268)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. (2013) (268)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. (2017) (262)
Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (260)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (2014) (254)
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. (2001) (240)
A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer. (2006) (228)
Carcinoma of unknown primary (CUP). (2009) (225)
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. (2000) (221)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (220)
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. (2017) (218)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study (2020) (211)
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. (2013) (207)
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up (2018) (205)
The role of Src in prostate cancer. (2007) (193)
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (2008) (191)
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. (2015) (190)
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. (2002) (188)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. (2016) (187)
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. (2014) (185)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. (2020) (185)
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. (2013) (184)
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. (2015) (176)
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). (2007) (176)
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies (2013) (175)
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. (2012) (174)
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. (2015) (171)
Targeting Continued Androgen Receptor Signaling in Prostate Cancer (2011) (168)
Cancer of unknown primary (CUP). (2005) (163)
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. (2009) (162)
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. (2000) (162)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. (2018) (161)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. (2020) (160)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (2012) (158)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. (2014) (156)
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma (2001) (154)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. (2020) (153)
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. (2001) (151)
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. (2013) (151)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. (2017) (151)
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer (2015) (150)
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (2022) (149)
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. (2003) (149)
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. (2014) (147)
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. (2014) (145)
Prostate cancer: ESMO Consensus Conference Guidelines 2012. (2013) (144)
Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. (2001) (143)
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). (2003) (140)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) (2019) (139)
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel (2015) (138)
Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high‐dose intrathecal methotrexate regimen (1996) (131)
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. (2004) (128)
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. (2020) (126)
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. (2012) (125)
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis (2017) (125)
Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. (1997) (125)
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. (2009) (124)
Active surveillance is the preferred approach to clinical stage I testicular cancer. (2013) (123)
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. (2003) (123)
Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). (2009) (123)
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) (2003) (122)
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. (2015) (118)
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure (2010) (117)
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. (2007) (115)
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. (2015) (114)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design (2022) (113)
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. (2015) (112)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities (2017) (112)
Carcinomas of an unknown primary origin—diagnosis and treatment (2011) (111)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
Managing Nonmetastatic Castration-resistant Prostate Cancer. (2019) (106)
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. (1998) (105)
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. (2014) (103)
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. (2018) (102)
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. (2015) (102)
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. (2015) (101)
Hypocalcaemia in patients with metastatic bone disease treated with denosumab. (2015) (100)
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. (2015) (100)
Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone (2012) (99)
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet (2011) (99)
Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (96)
Incidence of brain metastases in renal cell carcinoma treated with sorafenib. (2010) (95)
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. (2009) (95)
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (95)
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations (2019) (94)
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. (2016) (93)
Controversies in the management of clinical stage I testis cancer. (2006) (92)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. (2010) (92)
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. (2011) (91)
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. (1998) (91)
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. (2013) (91)
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. (2006) (87)
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. (2019) (87)
Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) (2019) (86)
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. (2013) (85)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer (2013) (83)
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. (2017) (83)
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events (2014) (79)
Sequential therapy in renal cell carcinoma (2009) (79)
A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. (2010) (78)
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). (2019) (78)
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. (2008) (77)
Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (77)
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat (2011) (76)
A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. (2003) (75)
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. (2014) (75)
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells (2006) (75)
Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone (2012) (75)
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. (2014) (75)
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. (2001) (75)
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. (2015) (74)
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. (2020) (74)
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA) (2018) (74)
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. (2015) (74)
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. (2021) (74)
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation (2008) (73)
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. (2015) (72)
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (72)
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. (2009) (72)
Treatment for patients with unknown primary cancer and favorable prognostic factors. (2009) (71)
Consensus on molecular imaging and theranostics in prostate cancer. (2018) (70)
Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy (1998) (70)
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer (2016) (70)
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
Chemotherapy in patients with teratoma with malignant transformation. (2007) (69)
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 (2016) (68)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (68)
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. (2000) (67)
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). (2014) (66)
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. (2018) (66)
Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. (2015) (65)
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms (2021) (65)
The postchemotherapy PSA surge syndrome. (2008) (64)
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (64)
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. (2002) (63)
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer (2013) (63)
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis (2018) (61)
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. (2013) (60)
Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (60)
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (60)
Who dies from prostate cancer? (2014) (59)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer (2015) (58)
High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. (1997) (58)
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium (2021) (58)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. (2017) (56)
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. (2017) (56)
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). (2016) (56)
Incidentally detected non-palpable testicular tumours in adults at scrotal ultrasound: impact of radiological findings on management Radiologic review and recommendations of the ESUR scrotal imaging subcommittee (2016) (56)
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. (2009) (55)
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate (2015) (55)
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. (2012) (55)
Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. (2019) (55)
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. (2021) (55)
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. (2005) (55)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer (2018) (53)
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. (2012) (52)
Advanced seminoma—Treatment results and prognostic factors for survival after first‐line, cisplatin‐based chemotherapy and for patients with recurrent disease (2003) (51)
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. (2015) (50)
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1 (2021) (50)
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial (2019) (49)
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. (2000) (49)
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. (2019) (49)
The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area (2005) (49)
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. (2017) (48)
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. (2021) (48)
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. (2014) (48)
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. (2015) (48)
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. (2015) (48)
Oxaliplatin in colorectal cancer: an overview. (2000) (48)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). (2013) (47)
EAU Guidelines on testicular cancer, 2011 update (2012) (47)
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population (2016) (47)
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2007) (47)
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. (2016) (46)
Intra-abdominal desmoplastic small round cell tumors: CT findings and clinicopathological correlations in 13 cases. (2005) (46)
Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy (2004) (45)
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. (2015) (45)
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. (2014) (45)
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. (2015) (45)
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. (2017) (45)
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients (2017) (45)
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. (2015) (45)
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study (2014) (45)
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). (2015) (45)
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) with or without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The Mainsail Trial (2012) (44)
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. (2017) (44)
New and emerging therapies for bone metastases in genitourinary cancers. (2013) (44)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model (2020) (44)
Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. (2016) (43)
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. (2022) (42)
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm (2020) (42)
A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. (2006) (41)
Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. (2019) (41)
Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. (2000) (41)
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. (2001) (41)
Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (2012) (41)
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. (2010) (40)
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. (2016) (40)
Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial (2015) (40)
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. (2013) (40)
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). (2021) (40)
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? (2010) (39)
Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. (2016) (39)
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial). (2014) (39)
The use of estramustine phosphate in the modern management of advanced prostate cancer (2011) (39)
[Breast cancer in the early stage]. (2012) (39)
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. (2012) (39)
753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY. (2014) (38)
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (38)
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. (2014) (38)
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (2018) (37)
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). (2020) (37)
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. (2012) (37)
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATIT (2019) (36)
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. (2014) (36)
Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial (2017) (36)
Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. (2015) (35)
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial (2022) (35)
PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) (2018) (35)
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. (2017) (35)
Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. (2011) (35)
Role of targeted therapy in the treatment of advanced prostate cancer (2010) (35)
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study (2016) (34)
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. (2009) (34)
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. (2015) (34)
Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. (2012) (34)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial (2019) (33)
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. (2008) (32)
Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel (2017) (32)
Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. (1998) (32)
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. (2012) (32)
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. (2017) (32)
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. (2016) (31)
Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) (2014) (31)
Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study (2019) (31)
Genitourinary tumors, non-prostate (2012) (31)
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. (2013) (31)
Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer (2013) (31)
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours (2002) (31)
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). (2004) (30)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. (2012) (30)
Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy? (1998) (30)
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents (2016) (30)
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. (2013) (29)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. (2017) (29)
Cisplatin‐based chemotherapy regimen (DECAV) for uterine sarcomas (2002) (29)
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer (2014) (29)
Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. (2014) (28)
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. (2010) (28)
Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (2020) (28)
Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). (2013) (28)
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. (2004) (27)
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial (2014) (27)
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. (2016) (27)
An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. (2020) (27)
Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. (2012) (27)
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy (2015) (26)
Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients (2004) (26)
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. (2009) (26)
Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. (2011) (26)
Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. (2013) (26)
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. (2020) (25)
The emerging role of antifolates in the treatment of malignant pleural mesothelioma. (2002) (25)
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. (2021) (25)
609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) (2020) (25)
Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours. (1997) (25)
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). (2011) (25)
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. (2012) (25)
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. (2016) (25)
Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. (2018) (24)
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. (2016) (24)
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. (2017) (24)
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. (2018) (24)
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. (2002) (23)
Efficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR). (2013) (23)
Identifying the Primary Site Using Gene Expression Profiling in Patients with Carcinoma of an Unknown Primary (CUP): A Feasibility Study from the GEFCAPI (2012) (23)
Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. (2016) (23)
Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors (2003) (23)
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. (2021) (22)
Germ cell tumors in patients infected by the human immunodeficiency virus (2001) (22)
Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). (2022) (22)
Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (22)
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study (2018) (22)
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. (2013) (22)
How to select targeted therapy in renal cell cancer. (2010) (22)
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study (2018) (21)
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). (2018) (21)
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer (2019) (21)
Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. (2013) (21)
Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (21)
A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. (2013) (21)
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. (2021) (21)
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA). (2020) (20)
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. (2015) (20)
Oxaliplatin in non-seminomatous germ-cell tumors. (2004) (20)
Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. (2013) (20)
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (20)
The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. (2020) (19)
Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings. (2009) (19)
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial (2021) (19)
Advancing therapies in metastatic castration-resistant prostate cancer (2018) (19)
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? (1999) (19)
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol (2017) (19)
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. (2016) (19)
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (19)
Germ-cell tumor survivors: the price for cure. (2002) (19)
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. (2015) (19)
Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study (2019) (18)
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC). (2020) (18)
Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). (2014) (18)
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. (2015) (18)
Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study). (2015) (18)
Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI) (2012) (18)
Carcinomas of an unknown primary site: a curable disease? (2008) (17)
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). (2016) (17)
Burned‐Out Testis Tumors in Asymptomatic Infertile Men: Multiparametric Sonography and MRI Findings (2017) (17)
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. (2019) (17)
Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers. (2012) (17)
A Phase II study of irinotecan in patients with advanced renal cell carcinoma (2003) (16)
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. (2002) (16)
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. (2017) (16)
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. (2014) (16)
Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (16)
Metachronous gonadal and extragonadal primaries, or late relapse of germ cell tumor? (2001) (16)
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). (2019) (16)
Novel and bone-targeted agents for CRPC. (2012) (16)
7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel (2011) (16)
Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia. (2014) (16)
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. (2014) (16)
LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (2017) (16)
Germ-cell tumours containing non germ-cell neoplasms (2001) (16)
SPECIFIC ENDOTHELIN‐A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER (2009) (16)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. (2017) (16)
Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma (2011) (15)
1091 PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID (2011) (15)
Enzalutamide in European and North American men participating in the AFFIRM trial (2014) (15)
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. (2017) (15)
Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium. (2020) (15)
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone (2016) (15)
Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. (2011) (15)
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (15)
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus (2010) (15)
Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. (2016) (14)
New agents in metastatic prostate cancer. (2009) (14)
Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study (2019) (14)
1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) (2017) (14)
Carcinoma of an Unknown Primary Site (2006) (14)
Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2013) (14)
Is there a withdrawal syndrome with abiraterone acetate (AA)? (2013) (14)
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone (2016) (14)
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. (2020) (14)
Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC). (2012) (14)
A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. (2012) (14)
Soft tissue sarcomas in HIV-infected adult patients. (1996) (14)
Taxanes: still a major weapon in the armamentarium against prostate cancer. (2013) (14)
Arades Trial: A First-in-Man, Open-Label, Phase I/II Safety, Pharmacokinetic, and Proof-of-Concept Study of ODM-201 in Patients (PTS) with Progressive Metastatic Castration-Resistant Prostate Cancer (MCRPC) (2012) (14)
Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302. (2015) (13)
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (13)
A phase II multicentre study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT). (2004) (13)
PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. (2017) (13)
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers (2006) (13)
Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). (2013) (13)
Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience. (2004) (13)
Redefining the IGCCCG classification in advanced non-seminoma (2019) (13)
Reponse to Cabazitaxel in the Postchemotherapy Setting in Crpc Patients Previously Treated with Docetaxel and Abiraterone Acetate (2012) (12)
Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. (2012) (12)
Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. (2013) (12)
Treatment of patients with specific subsets of carcinoma of an unknown primary site. (2006) (12)
[Therapeutic options for genitourinary cancers during the epidemic period of COVID-19]. (2020) (12)
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? (2021) (12)
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. (2021) (11)
Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience. (2020) (11)
705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACE (2011) (11)
Impact of Enzalutamide, An Androgen Receptor Signaling Inhibitor, on Time to First Skeletal Related Event (SRE) and Pain in the Phase 3 Affirm Study (2012) (11)
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. (2008) (11)
Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2013) (11)
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). (2019) (11)
[Primary mediastinal non-seminomatous germ-cell tumors: from clinics to biology]. (1997) (11)
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. (2019) (11)
Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial. (2014) (11)
Abiraterone acetate for metastatic prostate cancer (2012) (11)
579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC) (2021) (11)
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. (2001) (11)
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. (2022) (11)
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer. (2018) (11)
Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. (2015) (10)
610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations (2020) (10)
Safety of available treatment options for renal cell carcinoma (2016) (10)
Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). (2022) (10)
Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12). (2011) (10)
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. (2021) (10)
A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. (2006) (10)
648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS (2011) (10)
Isolated leptomeningeal metastasis from ovarian carcinoma: an unusual event. (1998) (10)
Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer (2018) (10)
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. (2020) (10)
Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound. (2021) (9)
Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC). (2021) (9)
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. (2013) (9)
PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients. (2014) (9)
Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (9)
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. (2021) (9)
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. (2014) (9)
The Association of p 21 ( WAF-1 / CIP 1 ) with Progression to Androgen-independent Prostate Cancer 1 (2002) (9)
Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study (2012) (9)
763PDUPDATED OVERALL SURVIVAL (OS) FROM THE PHASE 3 TRIAL, CA184-043: IPILIMUMAB (IPI) VS PLACEBO (PBO) IN PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (9)
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. (2015) (9)
Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials. (2014) (9)
PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? (2021) (9)
How to select amongst available options for the treatment of advanced RCC? (2012) (9)
A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC). (2012) (9)
Raltitrexed (‘Tomudex’) and oxaliplatin: an active out-patient regimen in malignant mesothelioma (1999) (9)
Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. (2013) (9)
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. (2022) (9)
[Locally advanced prostate cancer: definition, prognosis and treatment]. (2007) (9)
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (9)
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. (2012) (9)
Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). (2019) (8)
Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma (2001) (8)
Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. (2020) (8)
Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD (2019) (8)
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial. (2017) (8)
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer (2022) (8)
Everolimus Versus Axitinib as Second‐line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy (2017) (8)
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. (2020) (8)
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study. (2009) (8)
A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2017) (8)
The SEMITEP trial: De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET. (2020) (8)
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. (2022) (8)
Docetaxel-based chemotherapy in elderly patients (>= 75 years) with castration resistant prostate cancer (CRPC): A French National study of 175 patients (2008) (8)
[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial]. (2017) (8)
Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic (2018) (8)
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. (2020) (8)
The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials. (2017) (8)
Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. (2018) (8)
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer (2022) (7)
Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study (2008) (7)
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. (2017) (7)
Towards random sequencing or precision medicine in castration-resistant prostate cancer? (2014) (7)
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study (2021) (7)
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC). (2021) (7)
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study (2021) (7)
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. (2022) (7)
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy (2017) (7)
765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL. (2014) (7)
Randomized Trials in Patients with Carcinoma of an Unknown Primary Site: The Past, the Present, and the Future (2006) (7)
Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
783OBenefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO) (2017) (7)
Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours. (1996) (7)
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer (2015) (7)
Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. (2012) (7)
[Soft tissue sarcomas: general review]. (1994) (7)
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer (2020) (7)
Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). (2013) (7)
Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial. (2017) (7)
Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC). (2014) (6)
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. (2019) (6)
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events. (2014) (6)
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (2011) (6)
Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. (2018) (6)
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. (2020) (6)
TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). (2019) (6)
Peritoneal Carcinomatosis in Germ-Cell Tumor: Relations With Retroperitoneal Lymph Node Dissection (2000) (6)
Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (6)
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study (2019) (6)
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors. (2011) (6)
Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer. (2015) (6)
The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer. (2008) (6)
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]. (2003) (6)
TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC). (2020) (6)
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. (2017) (6)
A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. (2011) (6)
ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). (2019) (6)
Prognosis of renal cell carcinoma with bone metastases: Experience in 300 consecutive patients. (2017) (6)
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial (2021) (6)
Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. (2014) (6)
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). (2015) (6)
PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (2020) (6)
Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others. (2013) (6)
Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer (2009) (6)
Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. (2018) (6)
A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). (2021) (6)
A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). (2014) (6)
Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (5)
A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse. (2014) (5)
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. (2021) (5)
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. (2022) (5)
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. (2021) (5)
Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study (2012) (5)
1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY (2011) (5)
Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial. (2016) (5)
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial (2020) (5)
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302 (2022) (5)
Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. (2017) (5)
A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine. (2006) (5)
Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial. (2018) (5)
[Metastatic carcinoma of unknown origin]. (1998) (5)
[Testicular germ cell tumors]. (1998) (5)
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. (2021) (5)
Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials. (2013) (5)
Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P). (2013) (5)
Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921. (2020) (5)
ODM-201 and the CNS: A clinical perspective. (2014) (5)
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. (2013) (5)
Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study. (2020) (5)
Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA (2019) (5)
Testicular Cancer EAU Guidelines on (2016) (5)
Commentary on "Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase (2012) (5)
CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. (2021) (5)
Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). (2013) (5)
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. (2020) (5)
A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression. (2019) (5)
A risk-adapted strategy of radiotherapy and cisplatin-based chemotherapy in stage II seminoma: Results of a 20-year experience (2005) (5)
Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. (2014) (5)
Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (2011) (5)
No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors (2005) (5)
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12). (2014) (4)
Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results. (2015) (4)
Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. (2014) (4)
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. (2022) (4)
genitourinary tumours, prostateFinal overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC) (2016) (4)
What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses (2015) (4)
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial. (2021) (4)
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. (2022) (4)
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial (2022) (4)
20LBA What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses (2015) (4)
Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials (2016) (4)
Combining docetaxel with estramustine: back to the future? (2009) (4)
Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. (2013) (4)
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. (2019) (4)
[The French clinical trials ongoing (GETUG and AFU) on urothelial carcinomas, kidney and prostate cancers]. (2010) (4)
Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news? (2011) (4)
PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. (2022) (4)
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC). (2021) (4)
576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (2021) (4)
CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (2012) (4)
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain. (2011) (4)
Prognostic value of urinary N-telopeptide (uNTx) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (2008) (4)
Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies. (2018) (4)
Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study (2012) (4)
1200 Adults with Ewing's sarcoma: A retrospective study of 146 cases (1995) (4)
Whole-exome sequencing of single circulating tumor cells is a useful tool for studying the intrapatient genetic heterogeneity in metastatic prostate cancer. (2017) (4)
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? (2022) (4)
Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer (2008) (4)
862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials (2014) (4)
Chemotherapy for poor prognosis non seminomatous germ cell tumors (NSGCT): Should doses be reduced at first cycle to prevent acute respiratory distress syndrome (ARDS) in patients with multiple lung metastases? (2007) (4)
A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results. (2013) (4)
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? (2017) (4)
A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) (2007) (4)
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. (2022) (4)
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
Rucaparib or Physician's Choice in Metastatic Prostate Cancer. (2023) (4)
GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP). (2014) (4)
[Prognosis and predictive factors in prostate cancer]. (2009) (4)
Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary) (2007) (4)
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer. (2016) (4)
803PIndirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer (2017) (3)
PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE (2018) (3)
Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC). (2013) (3)
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). (2020) (3)
Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate. (2012) (3)
Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound. (2020) (3)
762PDIMPACT OF ENZALUTAMIDE ON SKELETAL RELATED EVENTS (SRES), PAIN AND QUALITY OF LIFE (QOL) IN THE PREVAIL TRIAL. (2014) (3)
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). (2022) (3)
3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials (2011) (3)
Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). (2015) (3)
223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) (2020) (3)
The TAXIF II Protocol Final Results: A Phase II Trial of High-Dose Chemotherapy Supported by Haematopoietic Stem Cell Transplantation in Patients with Disseminated Germ-Cell Tumors Failing Chemotherapy and with Adverse Prognostic Factors (2012) (3)
7153 POSTER Treatment (trx) Modalities After a Front Line Targeted Therapies in Patients (pts) With Metastatic Renal Cell Carcinoma (mRCC) (2011) (3)
Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events. (2014) (3)
Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. (2009) (3)
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD). (2018) (3)
A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC). (2012) (3)
Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials. (2017) (3)
The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC) (2012) (3)
PCN128 EQ-5D Utility Index in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Progression During or After First-Line Docetaxel Therapy (2011) (3)
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2023) (3)
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). (2013) (3)
LBA33What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis (2017) (3)
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. (2021) (3)
Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension. (2015) (3)
Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC). (2016) (3)
Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study (2018) (3)
An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary. (2010) (3)
690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX) (2020) (3)
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. (2022) (3)
Circulating endothelial cells and progenitor cells in metastatic renal cell cancer: Predictive value during anti-angiogenic therapy? (2007) (3)
The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mRCC patients: An integrated analysis of the TARGET and RECORD phase III trials data. (2012) (3)
Viable malignant cells after primary chemotherapy for disseminated non-seminomatous germ-cell tumors (NSGCT): An international validation study (2005) (3)
PRELIMINARY SAFETY, TOLERABILITY AND EFFICACY RESULTS OF KN026 (A HER2-TARGETED BISPECIFIC ANTIBODY) IN COMBINATION WITH KN046 (AN ANTI- PD-L1/CTLA-4 BISPECIFIC ANTIBODY) IN PATIENTS (PTS) WITH HER2 ABERRATED SOLID TUMORS (2020) (3)
U-Curved Relation Between Total Fasting Serum Cholesterol and Hostility: A Population-Based Study (2001) (3)
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study. (2022) (3)
Genitourinary tumors, prostate (2012) (3)
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region (2021) (3)
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer (2021) (3)
Hypocalcemia in patients with metastatic bone disease receiving denosumab. (2013) (3)
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC). (2019) (3)
796PEARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS. (2014) (3)
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy. (2016) (2)
Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial. (2014) (2)
648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC (2021) (2)
Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) (2016) (2)
Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study. (2017) (2)
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA). (2021) (2)
633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial (2020) (2)
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments? (2021) (2)
Abstract 5600: Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer (2018) (2)
Carcinomas of unknown primary site (1998) (2)
Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO) (2019) (2)
Effects of denosumab on bone resorption in patients with solid tumors and bone metastases: Comparison of serum-C telopeptide levels from two randomized, active-controlled, phase II trials (2008) (2)
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. (2009) (2)
Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial. (2021) (2)
Familial primary mediastinal nonseminomatous germ-cell tumors. (2004) (2)
Early PSA Decrease-based Nomogram to Predict Biochemical Failure in Patients with Localized Prostate Cancer Treated by Radiotherapy Only (2008) (2)
[Preclinical models of prostate cancer]. (2005) (2)
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics. (2014) (2)
Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients (2022) (2)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model (2020) (2)
Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial (2011) (2)
Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma. (2016) (2)
Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort. (2018) (2)
[Update on the use of estramustin in metastatic prostate cancer]. (2010) (2)
Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302. (2016) (2)
Treatment of hormone-naïve metastatic prostate cancer (2018) (2)
Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial. (2018) (2)
603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial (2021) (2)
713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL (2013) (2)
First-in-Class Small Molecule to Inhibit CYP11A1 And Steroid Hormone Biosynthesis. (2022) (2)
614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects (2020) (2)
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]. (2010) (2)
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses (2022) (2)
C176 PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER RECEIVING DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL (2011) (2)
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. (2023) (2)
Treatment of Castration-naive Metastatic Prostate Cancer. (2017) (2)
CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) (2019) (2)
784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS (2013) (2)
Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. (2012) (2)
Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC). (2018) (2)
Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]. (2017) (2)
Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder. (2012) (2)
Post hoc responder analysis of health-related quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials. (2018) (2)
Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis (2019) (2)
A phase II trial of high-dose chemotherapy (HDCT) supported by haematopoietic stem cell transplantation (HSCT) in patients (pts) with disseminated germ-cell tumors (GCTs) failing chemotherapy and with adverse prognostic factors: The TAXIF II protocol. (2009) (2)
[Treatment of testicular cancer]. (2013) (2)
KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2019) (2)
Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study. (2023) (2)
802TiPPROSPER: A PHASE 3 STUDY OF ENZALUTAMIDE IN NON-METASTATIC (M0) CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS. (2014) (2)
Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy. (2016) (2)
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. (2018) (2)
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. (2022) (2)
Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial. (2013) (2)
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study. (2020) (2)
P109 Efficacy outcomes by baseline prostate-specific antigen (PSA): Results from the Phase III AFFIRM trial (2013) (2)
Denosumab treatment for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer (2011) (2)
Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales) (2016) (2)
Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study (2022) (2)
Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors (2021) (2)
Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). (2010) (2)
Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell tumors (MGCT). (2014) (2)
[New drugs in metastatic castration-resistant prostate cancer]. (2010) (2)
2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC) (2015) (2)
614P Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance (2021) (2)
Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT). (2016) (2)
Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) <= 6 months - a post-hoc analysis of a randomised trial (2013) (2)
681 DENOSUMAB DELAYS DEVELOPMENT OF MULTIPLE BONE METASTASES IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER (2012) (2)
ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). (2021) (2)
A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS) (2017) (2)
MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) (2015) (2)
ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). (2018) (2)
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial (2021) (2)
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. (2022) (2)
Who dies from prostate cancer in a Western country? A multicenter analysis. (2013) (1)
Who should receive androgen deprivation therapy? (2012) (1)
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients? (2014) (1)
Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound. (2020) (1)
MP78-01 THE BURDEN OF SKELETAL-RELATED EVENTS ON PAIN OUTCOMES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (2014) (1)
The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls (2022) (1)
How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial (2016) (1)
A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. (2018) (1)
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease (2021) (1)
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC) (2021) (1)
A phase II study of alternating dose-dense chemotherapy in patients with poor-prognosis disseminated non-seminomatous germ cell tumors (NSGCT): Final results (2001) (1)
MP73-10 BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS (2015) (1)
97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (2013) (1)
900PPROGNOSTIC SIGNIFICANCE OF SERUM ALPHAFOETOPROTEIN EARLY DECLINE IN OVARIAN YOLK SAC TUMOR. (2014) (1)
Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial. (2021) (1)
629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study (2020) (1)
138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin (2020) (1)
1513PRISK FACTORS FOR HYPOCALCEMIA IN PATIENTS WITH CANCER RECEIVING DENOSUMAB. (2014) (1)
TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). (2019) (1)
Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies (2021) (1)
A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2019) (1)
Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer. (1994) (1)
[Strategies in castration-resistant prostate cancer]. (2011) (1)
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial. (2021) (1)
Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial. (2014) (1)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci ﬁ c Antigen Across Five Randomized Phase III Clinical Trials (2018) (1)
Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study. (2021) (1)
Abstract #2944: Molecular determinants of Docetaxel-resistance in prostate cancer cells (2009) (1)
Phase II study of salvage dose-dense chemotherapy in patients with disseminated non-seminomatous germ cell tumors (NSGCT): Final results (2001) (1)
Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. (2015) (1)
Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy. (2004) (1)
Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC). (2018) (1)
Localized testicular germ cell tumor surveillance: A Delphi consensus study. (2020) (1)
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. (2022) (1)
Use of 18F-FDG PET/CT to select candidates for active surveillance: Results of the SEMITEP trial of PET-directed strategy for stage 1 seminoma. (2018) (1)
The GETUG SEMITEP Trial: De-Escalating Chemotherapy in Good-Risk Metastatic Seminoma Based on Early FDG-PET/CT (2020) (1)
Abstract 4339: Prostate adenocarcinoma and intensive bone remodeling in a new prostate cancer IGR-CaP1 preclinical model derived from a human primary tumor (2010) (1)
Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. (2018) (1)
Associated With Primary Mediastinal Nonsemino-matous Germ Cell Tumors (1999) (1)
EAU Guidelines on testicular cancer : 2011 update 129 Table 1 Recommended pathologic classification (2017) (1)
Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial. (2022) (1)
P057 PROSPER: A phase 3 study of enzalutamide in non-metastatic (M0) castration-resistant prostate cancer (CRPC) patients (2014) (1)
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. (2018) (1)
802PPatient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial (2017) (1)
340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (2020) (1)
Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study. (2017) (1)
2554 Clinical outcome of initially metastatic hormone sensitive prostate cancer (HSPC) in real life population from a single center: Comparison with initially metastatic HSPC patients included in the GETUG-AFU 15 trial (2015) (1)
[How to manage bone metastasis in prostate cancer. A case report]. (2010) (1)
Fatigue and health behaviors in cancer survivors: A cross-sectional population based study. (2017) (1)
[Management of clinical stage I testicular germ cell tumours]. (2007) (1)
Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy. (2013) (1)
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity. (2022) (1)
Stage II Seminoma: Why Chemotherapy Should Remain a Standard (2023) (1)
MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302 (2014) (1)
127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase I (2012) (1)
AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies (2012) (1)
582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD) (2021) (1)
1374P Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial (2022) (1)
Survival outcomes of pre-metastatic castration-resistant prostate cancer and the burden of developing metastasis: A systematic literature review. (2018) (1)
Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study (2019) (1)
Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial. (2013) (1)
Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). (2013) (1)
647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer (2021) (1)
Reply to Araki et al. (2013) (1)
Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157]. (2017) (1)
Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months (2020) (1)
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. (2012) (1)
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide. (2021) (1)
564 Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (2015) (1)
Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC). (2019) (1)
Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol (2018) (1)
Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. (2023) (1)
Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. (2014) (1)
Abstract 2995: Loss of SHISA3 is an early event of the epithelial-to-mesenchymal transition associated with chemoresistance in prostate cancer (2015) (1)
Ultrasound and Magnetic Resonance Imaging of Burned-Out Testicular Tumours: The Diagnostic Keys Based on 48 Cases (2022) (1)
861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 (2014) (1)
F01*New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) (2015) (1)
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2008) (1)
ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC). (2017) (1)
Biennial report on genitourinary cancers. (2016) (1)
Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer. (2022) (1)
Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS. (2022) (1)
Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. (2012) (1)
Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. (2016) (1)
IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone (2018) (1)
Cross-validation of a new prognostic index integrating tumor marker decline in patients with relapsed disseminated germ cell tumors. (2009) (1)
Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER (2018) (1)
7162 Post-chemotherapy residual masses <15 mm in patients with metastatic non seminomatous germ cell tumors: is resection required? (2009) (1)
[Inappropriate antidiuretic hormone secretion disclosing a second primary lung cancer 5 years after complete remission of a small cell lung carcinoma]. (1996) (1)
Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer (2021) (1)
Reply to Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy by C. Heyns (2010) (1)
Expanding horizons in metastatic prostate cancer treatment (2011) (1)
A phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem) (GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract (2005) (1)
630P Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial (2021) (1)
580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity (2021) (1)
Abstract 1597: A novel preclinical model of prostate cancer bone metastasis derived from a human primary tumor (2011) (1)
896Intermittent hormonal therapy for non localized prostate cancer (2005) (1)
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
Resistance to Chemical Castration: Second-Line Hormonal Treatment (2012) (1)
7161 Stage I seminoma: can 18Flurorodeoxyglucose positron emission tomography (FDG-PET) predict occult dissemination? Preliminary results of a phase II study (2009) (1)
Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients (2019) (1)
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. (2019) (1)
668 Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302 (2015) (1)
2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis (2015) (1)
FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2016) (1)
Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database. (2018) (1)
7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial (2011) (1)
CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide. (2020) (1)
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial. (2017) (1)
A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC): Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel (2017) (1)
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials (2021) (1)
Does the kinetic of tumor marker decline predict outcome in patients with relapsed disseminated germ-cell tumors treated by high-dose or conventional chemotherapy? An analysis of the IT94 randomized trial (2008) (1)
4525 POSTER Self evaluation of side-effects of patients treated sequentially with sunitinib and sorafenib in kidney cancer (2007) (1)
A Statistical Approach to Determine the Optimal Duration of Post‐Treatment Follow‐Up: Application to Metastatic Nonseminomatous Germ Cell Tumors (2017) (0)
[Prostate cancer: future strategies for chemotherapy management]. (2007) (0)
Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2023) (0)
[Management of metastatic testicular germ cell tumors]. (2019) (0)
Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply (2018) (0)
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. (2023) (0)
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC). (2018) (0)
Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients. (2014) (0)
Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells (2015) (0)
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. (2023) (0)
Rechallenge with axtinib in metastatic renal cell carcinoma (mRCC) - Experience from Gustave Roussy (2016) (0)
869 Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid (2014) (0)
7020 Performance status and interval from first-line docetaxel-based chemotherapy to progression are significant prognostic factors in patients with castration-resistant prostate cancer receiving second-line chemotherapy (2009) (0)
Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study (2021) (0)
Impact of PSA decrease at the end of radiotherapy for localized prostate cancer on clinical recurrence and specific cause survival (2007) (0)
VID-06.09: Transperitoneal approach for laparoscopic retro peritoneal lymph node dissection (RPLND) for large residual mass (2007) (0)
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921) (2020) (0)
The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) (2017) (0)
O10 Enzalutamide, an androgen receptor signaling inhibitor, improves overall survival, time to first skeletal related event and pain (2012) (0)
105 cases of renal tumors in patients age 15 to 35: A specific entity? Experience of the Gustave Roussy Institute. (2014) (0)
MP29-02 EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS (2023) (0)
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients (2016) (0)
MP29-01 RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS (2023) (0)
Combination o f R altitrexed a nd O xaliplatin I s a n A ctive Regimen i n M alignant M esothelioma: Results o f a P hase I I S tudy (2003) (0)
Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study. (2023) (0)
Abiraterone in Metastatic Prostate Cancer. (2017) (0)
259 INVITED Bone Targeting (2011) (0)
Diagnostic and therapeutic management of carcinoma of unknown primary (2006) (0)
A Female Patient with Pleural Extension of an Unknown Primary Carcinoma (2006) (0)
Risk of late relapse after surveillance for stage I mixed (M) or non seminomatous (NS) testicular germ cell tumors (TGCT). (2006) (0)
K. Syrigos (ed). Prostate Cancer: Biology, Diagnosis and Management (2003) (0)
Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. (2019) (0)
PRO: Treatment Intensification in Poor Prognosis Germ Cell Tumors (2017) (0)
[Prostate tumors]. (2010) (0)
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (2011) (0)
Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial. (2021) (0)
Continuous Infusion Bleomycin in the Bep Regimen: A Therapeutic Alternative in the Management of Patients with Germ-Cell Tumors? (2012) (0)
MP27-05 EFFICACY AND SAFETY OF DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH AND WITHOUT PRIOR LOCAL THERAPY WITH RADICAL PROSTATECTOMY OR RADIOTHERAPY (2022) (0)
OC-0609 Radiotherapy quality assurance of the PEACE-1 trial: Initial results of individual case reviews (2022) (0)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc (2019) (0)
838TiPARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC) (2017) (0)
104 Overall survival with cabazitaxel is strongly related to PSA response: Results of a retrospective registry in metastatic castration resistant prostate cancer (mCRPC) (2013) (0)
Efficacy and Toxicity Following Salvage High-Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer after Radiotherapy: A Single Center Retrospective Analysis (2019) (0)
Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study. (2023) (0)
[Management of localized germ-cell tumours of the testis]. (2007) (0)
626P Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study (2021) (0)
Abstract 4664: MatchR a preclinical platform of models resistant to innovative therapies (2023) (0)
LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2019) (0)
Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. (2012) (0)
826PCONTRIBUTION OF TUMOR BURDEN AND BODY COMPOSITION PARAMETERS AS PROGNOSTIC FACTORS OF METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED BY TARGETED THERAPY. (2014) (0)
655MO A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study (2021) (0)
Medical therapy for renal cell cancer with pancreatic metastases: Experience of the Gustave Roussy Institute. (2015) (0)
Clinical and Safety Outcomes of TALAPRO-2: a 2-Part Phase 3 Study of Talazoparib (TALA) in Combination with Enzalutamide (ENZA) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2019) (0)
596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration (2015) (0)
Guidelines EAU Guidelines on Testicular Cancer : 2011 Update (2012) (0)
Abstract B131: Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial (2023) (0)
Dexamethasone in pretreated men with metastatic castration-resistant prostate cancer (mCRPC): A prospective study. (2018) (0)
A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment. (2019) (0)
TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT). (2018) (0)
Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. (2014) (0)
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study (2020) (0)
Abiraterone in Metastatic Prostate Cancer. (2017) (0)
Effects of prior local therapy by radical prostatectomy or radiotherapy on the efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer from aramis (2022) (0)
Abstract 823: Integration of microRNA and gene expression signatures from several models of Docetaxel-resistant prostate cancer cell lines (2012) (0)
108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months (2013) (0)
[Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer]. (2001) (0)
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? (2015) (0)
Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma—A multicenter retrospective analysis. (2020) (0)
PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer (2015) (0)
Efficacy and safety of the APE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia. (2012) (0)
Early replacement of CT scanning by abdomino-pelvic ultrasound as a safe alternative in the follow-up of patients with germ cell tumors. (2017) (0)
A prospective study of carboplatin-etoposide in docetaxel-pretreated patients with hormone-refractory prostate cancer (HRPC): Clinical activity and correlation with neuroendocrine features (2007) (0)
F24Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): retrospective analysis (2015) (0)
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. (2022) (0)
Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC). (2020) (0)
Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial. (2023) (0)
824PDIFFERENCES BETWEEN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO DEVELOP BRAIN METASTASES (BM) VERSUS THOSE WHO DO NOT. (2014) (0)
Chapter 2 PSA as a marker of progression and response in advanced prostate cancer (2010) (0)
Thermal ablation for the treatment of bone metastases (BM) in patients (pts) with metastatic renal cell carcinoma (mRCC): Experience from IGR. (2015) (0)
Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program. (2015) (0)
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]. (2020) (0)
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC). (2022) (0)
[High dose chemotherapy and germ cell tumor]. (2011) (0)
Poor-Prognosis Germ Cell Tumours (2015) (0)
Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer. (2023) (0)
P108 Baseline characteristics and efficacy outcomes of patients with long-term exposure to enzalutamide during the Phase III AFFIRM trial (2013) (0)
Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial (2019) (0)
Reply to K. Lu. (2015) (0)
Abstract 400: Functional, structural and binding studies of the atypical ER-resident protein FKBP7, a potential target in chemoresistant prostate cancer (2022) (0)
A Dose-Escalation Study for High-Dose-Rate Brachytherapy Boost in Intermediate- and High-Risk Prostate Cancer Patients (2015) (0)
ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer. (2017) (0)
Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas (2002) (0)
P119 Design of a randomized, open-label trial adding custirsen, a novel clusterin inhibitor, to cabazitaxel/prednisone in second-line treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): The AFFINITY phase 3 study (2013) (0)
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol (2017) (0)
[Preface]. (2020) (0)
Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate. (2012) (0)
Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. (2010) (0)
765 Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial (2016) (0)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)– Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity (2022) (0)
685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response (2020) (0)
Immunosuppressed Microenvironment – An Emerging Target in Prostate Cancer Management (2014) (0)
A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer. (2018) (0)
LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL (2022) (0)
Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study (2021) (0)
PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY (2020) (0)
Second-line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. (2012) (0)
First-line Systemic Therapy in Patients Ineligible (‘Unfit’) to Receive a Cisplatin-based Regimen – Literature Review, Recommendations and Potential Use of Vinflunine in Combination or as Monotherapy (2013) (0)
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
638P Meningeal metastases (MM) in patients with metastatic castration resistant prostate cancer (mCRPC) (2020) (0)
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? (2022) (0)
981 Should the primary site be treated in patients with de novo metastatic prostate cancer (2014) (0)
648P Abiraterone and dexamethasone in castration-resistant prostate cancer: Biological response after switch or rechallenge (2020) (0)
MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION (2019) (0)
Adaptation of chemotherapy to the decline tumor markers in patients with poor prognosis nonseminomatous germ cell tumors:Real-world French experience. (2021) (0)
Metastatic Germ Cell Tumours (2014) (0)
556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis (2015) (0)
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]. (2022) (0)
Regulation of eIF4F complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer (2016) (0)
24 colour multifish karyotype showing the complexity of the genomic rearrangements with rearranged c (2011) (0)
PD32-06 LONG-TERM SAFETY AND ANTITUMOR ACTIVITY OF ODM-201 IN CHEMOTHERAPY AND CYP17-INHIBITOR NAÏVE PATIENTS FROM THE ARADES AND THE ARAFOR TRIALS (2016) (0)
Androgen Receptor Pathway in Prostate Cancer: Old Target and New Drugs (2012) (0)
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history. (2023) (0)
Prognostic role of body composition parameters in renal cell carcinoma (RCC). (2012) (0)
PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
695TiP ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region) (2020) (0)
Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity (2021) (0)
Abstract 5754: Temozolomide therapy for progressive metastatic paraganglioma/pheochromocytoma: SDHB mutation as a prognosis biomarker for efficacy (2012) (0)
Abstract 358: A prospective study of prostate cancer metastases identifies an androgen receptor activity-low, stemness program associated with resistance to androgen receptor axis inhibitors and unveils mechanisms of clonal evolution (2021) (0)
Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1 (2021) (0)
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]. (2020) (0)
Abstract 3079: Characterization of the molecular heterogeneity of circulating tumor cells in metastatic prostate cancer (2013) (0)
Genomic landscape of metastatic platin-resistant urothelial cancer patients. (2015) (0)
Development a nd V alidation o f a P rognostic M odel t o P redict the L ength o f S urvival i n P atients W ith C arcinomas o f a n Unknown P rimary S ite (2002) (0)
Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC). (2018) (0)
Advanced prostate cancer – lessons from the past for success in the future (2012) (0)
First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC). (2015) (0)
7158 POSTER Impact of Targeted Therapies on Muscle Loss and Adipose Tissue in Metastatic Renal Cell Carcinoma (mRCC) (2011) (0)
864 Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials (2014) (0)
213PRELATIONSHIP OF BONE SCAN INDEX AND PROGRESSION-FREE SURVIVAL DATA FOR METASTATIC CRPC PATIENTS WHO RECEIVED ODM-201. (2014) (0)
MP-21.11: Laparoscopic post chemotherapy retro peritoneal lymph node dissection for residual mass: initial results (2007) (0)
A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC). (2016) (0)
1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC) (2022) (0)
Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC). (2012) (0)
No Beyer et al consensus Ann Oncol 2012 (2012) (0)
PD15-07 IMPACT OF BONE-TARGETED THERAPIES IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ON ENZALUTAMIDE: A POST HOC ANALYSIS OF PREVAIL (2019) (0)
Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer. (2022) (0)
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA). (2015) (0)
1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study (2022) (0)
Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Castration-resistant , CYP 17 Inhibitor-naïve Prostate Cancer : Results from Extended Follow-up of the ARADES Trial (2018) (0)
4001 ORAL PSA decrease at the end of the course of radiotherapy for prostate cancer has a significant impact on biochemical failure and clinical recurrence (2007) (0)
713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial (2021) (0)
Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC). (2015) (0)
Reply to C. Ren et al. (2018) (0)
Abstract 4953: Whole-exome sequencing of single circulating tumor cells according to epithelial-mesenchymal marker expression in metastatic prostate cancer (2016) (0)
1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB) (2022) (0)
CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent (2016) (0)
Selected Abstracts presented at the XIII Symposium of the International Society of Oncology Pharmacy Practitioners, 9–11 May 2012, Melbourne, Australia (2012) (0)
651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study (2020) (0)
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. (2023) (0)
Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy? (2010) (0)
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer (2022) (0)
PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2014) (0)
Cog-Pro: Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer (2016) (0)
[Difficult clinical cases in prostate cancer: multidisciplinary staff, the rational principles of adjuvant therapy and other therapeutic options]. (2006) (0)
Localized testicular germ cell tumor (TGCT) surveillance: A Delphi consensus study. (2021) (0)
Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Chemotherapy-naïve and CYP 17 Inhibitor-naïve Patients : Follow-up from the ARADES and ARAFOR Trials (2018) (0)
Health resource utilization and patient burden associated with SREs in a randomized controlled trial setting. (2012) (0)
Expanding horizons in metastatic prostate cancer treatment. (2011) (0)
MP11-14 TREATMENT DURATION AND LONG-TERM SAFETY AND TOLERABILITY WITH DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (nmCRPC): ARAMIS ROLLOVER STUDY (2023) (0)
Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study. (2023) (0)
Factors associated with depressive symptoms in patients with metastases from prostate cancer (2007) (0)
Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol (2018) (0)
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate. (2021) (0)
581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1 (2021) (0)
P126 Can we predict which patients with metastatic Renal Cell Carcinoma (mRCC) will develop Brain Metastases (BM) (2014) (0)
PF1-091ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer (2016) (0)
646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer (2021) (0)
Androgen Pathway-Targeted Agents: Prostate Cancer as a Metabolic Disease (2015) (0)
Frequency of liver test increases on abiraterone acetate in men with castrate-resistant prostate cancer (CRPC): Natural history, management, and outcome. (2018) (0)
1420P The pharmacokinetics and the pharmacodynamic effect of ODM-208, an inhibitor of cholesterol side-chain cleavage enzyme (CYP11A1) (2022) (0)
1672P Tumor and immune cell dynamics at single-cell resolution on combined PARP inhibition and anti-PD-L1 therapy (2022) (0)
[Metastasis from unknown primary neoplasm. The demands of the clinician in 2010 and in the future]. (2010) (0)
222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial (2020) (0)
Research Highlights (2021) (0)
Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403). (2010) (0)
624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound (2020) (0)
Chapter 6 Systemic treatment: immunotherapy (2010) (0)
Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2. (2009) (0)
– Prostate Cancer – Editor ’ s Choice Managing Nonmetastatic Castration-resistant Prostate Cancer (2019) (0)
Abstract 1250: ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model (2021) (0)
567 Safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials (2015) (0)
Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies. (2015) (0)
Phase II study of the combination of vinorelbine, cisplatin, and tirapazamine in inoperable non-small cell lung cancer (NSCLC) (2000) (0)
1016: Randomized Trial of Denosumab Versus Zoledronic Acid in Prostate Cancer Patients with Bone Metastases and Elevated Bone Turnover Markers After Receiving Zoledronic Acid Therapy (2007) (0)
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial (2023) (0)
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer (2022) (0)
7166 Predicting and preventing thrombo-embolic events in patients with germ-cell tumors receiving cisplatin-based chemotherapy (2009) (0)
How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study (2022) (0)
Clinical News. (2017) (0)
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. (2023) (0)
1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer (2022) (0)
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. (2012) (0)
Original article Familial primary mediastinal nonseminomatous germ-cell tumors (2004) (0)
Abstract 956: Role of the cell cycle regulator LZTS1 in docetaxel resistance of prostate cancer cells and overcoming the docetaxel resistance by cell cycle pharmacological inhibitors. (2013) (0)
MP27-13 LONG-TERM SAFETY OF DAROLUTAMIDE AMONG PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO RECEIVED MORE THAN 4 YEARS OF THERAPY (2022) (0)
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (0)
2513 New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) (2015) (0)
Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
Second Line Treatment in Metastatic Papillary Renal Cell Carcinoma: Retrospective Analysis of a 48 Patients Cohort (2012) (0)
Abstract 1114: Novel preclinical models of aggressive variants of castration-resistant prostate cancer (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Karim S. Fizazi?

Karim S. Fizazi is affiliated with the following schools:

University of Liverpool
Université de Montréal
Tampere University
Paris-Saclay University
University of British Columbia
Cardiff University
Sapienza University of Rome
Massachusetts General Hospital

Karim S. Fizazi's Academic­Influence.com Rankings

Karim S. Fizazi's Degrees

Why Is Karim S. Fizazi Influential?

Karim S. Fizazi's Published Works

Published Works

What Schools Are Affiliated With Karim S. Fizazi?

Karim S. Fizazi's AcademicInfluence.com Rankings